Tumor markers are substances present in malignant tumor cells, or produced abnormally by malignant tumor cells, or produced in response to tumor stimulation, which can indirectly reflect tumor growth, and are more ideal and desired tumor markers with high sensitivity and specificity, and can also make judgments on tumor localization, tumor staging, malignancy, tumor size, and treatment effects. At present, more than one hundred kinds of tumor markers have been discovered clinically, but none of them is a very ideal tumor marker, because tumor marker is a reference value for diagnosing tumor, and it is not possible to diagnose tumor by the increase of tumor marker alone. In addition, lymphoma is a malignant tumor of the lymphopoietic tissue system, which can be divided into Hodgkin’s lymphoma and non-Hodgkin’s lymphoma according to lymphocytes, and is not the same as solid tumors. Lymphoma has no tumor markers at the time of onset, and the International Prognostic Index (IPI) is usually used in clinical treatment to evaluate the prognostic risk and treatment of patients. The IPI is a combination of blood sedimentation, serum, lactate dehydrogenase, age, beta 2 microglobulin, and mass size. If a patient has a low IPI score, the prognostic risk is low, and if not, the risk is high.